Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 5/20 | 0.52 |
| ▸ | NMT2 | O60551 | 4/20 | 0.52 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | FURIN | P09958 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30558181 | 0.99 | NMT1 (0.50) | NMT1NMT2SLC15A2GRIN2DGRIN3B | |
| SCHEMBL31593363 | 0.92 | GRIN2D (0.48) | NMT1NMT2SLC15A2GRIN2DGRIN3B | |
| SCHEMBL29867569 | 0.91 | NMT1 (0.51) | NMT1NMT2SLC15A2GRIN2DGRIN3B | |
| SCHEMBL30964333 | 0.90 | SLC15A2 (0.51) | NMT1NMT2SLC15A2FURIN | |
| SCHEMBL29364543 | 0.88 | NMT1 (0.47) | NMT1NMT2TLR2 | |
| SCHEMBL29706336 | 0.88 | SLC15A2 (0.50) | NMT1NMT2SLC15A2 | |
| SCHEMBL30446798 | 0.88 | SLC15A2 (0.55) | NMT1NMT2SLC15A2TLR2 | |
| SCHEMBL379079 | 0.87 | NMT2 (0.45) | NMT1NMT2SLC15A2FURIN | |
| SCHEMBL379078 | 0.87 | NMT2 (0.45) | NMT1NMT2SLC15A2FURIN | |
| SCHEMBL827832 | 0.87 | NMT2 (0.45) | NMT1NMT2TLR2FURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240041740-A1 | SKIN PEEL COMPOSITIONS | GLO PHARMA INC (US) | 2024-02-08 | — | — | US | disclosed |
| US-20230270635-A1 | METHODS AND COMPOSITIONS FOR COSMETIC APPLICATIONS | GLO PHARMA INC (US) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270635-A1 | METHODS AND COMPOSITIONS FOR COSMETIC APPLICATIONS | CUTA, GLA, LIPA | NMT1 2462/4885NMT2 1989/4885SLC15A2 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.